Harmony Biosciences Holdings (HRMY) EBITDA Margin (2020 - 2026)
Harmony Biosciences Holdings (HRMY) reported EBITDA Margin of 17.31% for Q1 2026, down 1313.0% on a YoY basis from 1.43% in Q1 2025, and up 9.46% sequentially from 15.82% in Q4 2025.
Harmony Biosciences Holdings (HRMY) EBITDA Margin (2020 - 2026) Analysis & Trends
Harmony Biosciences Holdings (HRMY) has 7 years of EBITDA Margin data on file, last reported at 17.31% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 1313.0% year-over-year to 17.31%; the trailing twelve-month figure through Mar 2026 stood at 21.08% (down 511.0% YoY), and the FY2025 full-year result was 24.0%, down 269.0% from the prior year.
- EBITDA Margin rose to 17.31% in Q1 2026, from 15.82% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 40.25% in Q3 2023 to a low of 10.15% in Q3 2022.
- A 5-year average of 27.37% and a median of 30.45% in 2025 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin soared 3010 bps in 2023 and sank 2259 bps in 2024, its largest moves.
- Tracing HRMY's EBITDA Margin over 5 years: stood at 37.11% in 2022, then slumped by 36 bps to 23.87% in 2023, then gained by 16 bps to 27.69% in 2024, then tumbled by 43 bps to 15.82% in 2025, then climbed by 9 bps to 17.31% in 2026.
- Business Quant data shows HRMY's EBITDA Margin at 17.31% in Q1 2026, 15.82% in Q4 2025, and 27.35% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Harmony Biosciences Holdings | 2.07 Bn | 1.55 Bn | 170.88 Mn | 17.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.31% |
| Dec 31, 2025 | 15.82% |
| Sep 30, 2025 | 27.35% |
| Jun 30, 2025 | 24.03% |
| Mar 31, 2025 | 30.45% |
| Dec 31, 2024 | 27.69% |
| Sep 30, 2024 | 33.17% |
| Jun 30, 2024 | 12.36% |
| Mar 31, 2024 | 33.65% |
| Dec 31, 2023 | 23.87% |
| Sep 30, 2023 | 40.25% |
| Jun 30, 2023 | 34.95% |
| Mar 31, 2023 | 33.93% |
| Dec 31, 2022 | 37.11% |
| Sep 30, 2022 | 10.15% |
| Jun 30, 2022 | 30.94% |
| Mar 31, 2022 | 32.30% |
| Dec 31, 2021 | 31.39% |
| Sep 30, 2021 | 26.08% |
| Jun 30, 2021 | 31.58% |